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Abstract
Background: Human heart failure is a complex disease that manifests from multiple genetic and
environmental factors. Although ischemic and non-ischemic heart disease present clinically with
many similar decreases in ventricular function, emerging work suggests that they are distinct
diseases with different responses to therapy. The ability to distinguish between ischemic and non-
ischemic heart failure may be essential to guide appropriate therapy and determine prognosis for
successful treatment. In this paper we consider discriminating the etiologies of heart failure using
gene expression libraries from two separate institutions.
Results: We apply five new statistical methods, including partial least squares, penalized partial
least squares, LASSO, nearest shrunken centroids and random forest, to two real datasets and
compare their performance for multiclass classification. It is found that the five statistical methods
perform similarly on each of the two datasets: it is difficult to correctly distinguish the etiologies of
heart failure in one dataset whereas it is easy for the other one. In a simulation study, it is confirmed
that the five methods tend to have close performance, though the random forest seems to have a
slight edge.
Conclusions: For some gene expression data, several recently developed discriminant methods
may perform similarly. More importantly, one must remain cautious when assessing the
discriminating performance using gene expression profiles based on a small dataset; our analysis
suggests the importance of utilizing multiple or larger datasets.
Background
Human heart failure is a complex disease diagnosed in
over 500,000 American people every year, causing more
than 250,000 deaths annually. It may arise from coronary
atherosclerosis, exposure to toxins, infection, inflamma-
tion, valvular disease leading to volume/pressure over-
load, or an underlying genetic or idiopathic event [1-3].
Emerging work suggests the heterogeneity of heart failure.
For example, patients with ischemic heart failure have
decreased survival compared to the non-ischemic heart
failure [4,5] and respond differently to therapies [6-9].
Although benefits can be achieved using ischemic heart
Published: 24 August 2005
BMC Bioinformatics 2005, 6:205 doi:10.1186/1471-2105-6-205
Received: 13 April 2005
Accepted: 24 August 2005
This article is available from: http://www.biomedcentral.com/1471-2105/6/205
© 2005 Huang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Bioinformatics 2005, 6:205 http://www.biomedcentral.com/1471-2105/6/205
Page 2 of 15
(page number not for citation purposes)
failure therapy for idiopathic heart failure (and vice
versa), cure rates will be markedly diminished, and
unwarranted toxicities problems will be encountered. It
may be critical to distinguish these characteristically simi-
lar but clinically somewhat distinct heart failures, to better
optimize therapy. The ability to distinguish between dif-
ferent etiologies of heart failure may be essential to guide
appropriate therapy and determine prognosis for success-
ful treatment.
A new approach to discriminating etiologies of heart fail-
ure is gene expression profiling using DNA microarray
technology, which has been shown to be promising in the
diagnosis of human diseases or subdiseases, especially in
cancer [10-12]. Recent genomic studies by three separate
groups have demonstrated a distinct etiology dependent
genomic pattern in the failing heart [13-16]. These studies
offer hope that the microarray gene expression analysis
could potentially add to conventional laboratory
approaches to diagnose different underlying etiologies of
heart failure while simultaneously enhance prognostic cri-
teria. It was hypothesized that heart failure arising from
different underlying etiologies present with different gene
expression patterns and that these differences could be
used as a diagnostic tool. Here we test the hypothesis with
two human heart failure datasets from different
institutions.
Sample classification with gene expression data is statisti-
cally challenging due to the "small n, large p" problem
[17]: the number of samples n is much smaller than the
number of genes or predictors p. In our first dataset, we
have n = 30 and p > 20000. Many new statistical methods
have been developed or adapted to face the challenge.
With more and more new methods emerging and existing
methods being adapted, it becomes increasingly compel-
ling for practitioners to compare and assess their perform-
ance, but there are few such comparative studies [18-20].
Huang and Pan [19] compared several methods, includ-
ing partial least squares (PLS) [21], nearest shrunken cen-
troid (SC) [12], and a penalized PLS (PPLS), for binary
classification of gene expression data. They found that
these methods are competitive. More recently, some
authors [22,20] have shown the promising performance
of least absolute shrinkage and selection operator
(LASSO) [23] and random forest (RF) [24]. It is our main
goal to evaluate and compare these methods using two
human heart failure datasets. For this purpose, we also
extend the PPLS, originally proposed for binary classifica-
tion, to multiclass classification. We found that the above
five statistical methods perform similarly. Furthermore,
our analysis stresses the importance of utilizing multiple
datasets for classification purposes.
Results
Minnesota data
Myocardial tissue samples from the left ventricular apex of
patients with severe refractory heart failure were collected
at the time of the left ventricular assist device (LVAD)
placement at the University of Minnesota Medical School.
A total of 30 tissue samples were processed for microarray
analysis on the Affymetrix Human Genome U133A chip
containing ~22,000 genes. The initial data analysis was
completed using Affymetrix Microarray Suite (MAS 5.0). A
more complete description on the data is provided in
[25].
The heart failure patients are divided into three classes
according to the underlying etiology. Patients with clinical
ECHO and EKG evidence, history of previous myocardial
infarctions, and direct observation of the heart for confir-
mation of infarction at the time of LVAD implantation are
defined as ischemic. Patients with an ischemic etiology
were further divided into two classes: patients with
ischemia but without acute myocardial infarctions
(ischemic class) and patients with ischemia that have had
an acute myocardial infarctions within ten days of LVAD
implant (IM class), the remaining patients were assigned
to the idiopathic class. Among the total 30 samples, 10 of
them are ischemic, 7 are IM and 13 are idiopathic.
PGA data
The PGA data were obtained in another heart failure study
conducted at the Cardio-Genomics PGA (Programs for
Genomic Applications) at the Harvard Medical School.
Myocardial samples were collected from patients under-
going heart transplantation whose failure arises from dif-
ferent etiologies (e.g. idiopathic, ischemic, alcoholic,
valvular, and hypertrophic) and from normal organ
donors whose hearts were not used for transplants. The
transcriptional profile of the mRNA in these samples was
also measured with Affymetrix oligonucleatide microarray
technology. HG-U133 plus 2 chips containing 54,675
probe sets were used and data were analyzed in MAS 5.0.
In the PGA data set there were 11 normal samples, 11
ischemic samples and 14 idiopathic samples. The PGA
dataset is publicly available at Genomics of Cardiovascu-
lar Development, Adaptation, and Remodelling. NHLBI
Program for Genomic Applications, Harvard Medical
School with URL: http://www.cardiogenomics.org.
In order to make the results comparable to those based on
the HG-U133A chips used in the Minnesota data, we
matched the probe sets on a HG-U133 plus 2 chip with
those on a HG-U133A chip. Only six probe sets on the
HG-U133 plus 2 chip could not be found on a HG-U133A
chip. Hence we used the remaining 22277 ( = 22283 - 6)
probe sets in the following analyses with the PGA data.BMC Bioinformatics 2005, 6:205 http://www.biomedcentral.com/1471-2105/6/205
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Classification with Minnesota data: One-against-others 
approach
Table 1 reports the LOOCV misclassification errors of the
five classification methods for the Minnesota data with
models starting from different numbers of top ranked
genes ranging from 50 to all genes. Four kinds of errors are
reported for each method: three one-against-others  two-
class LOOCV misclassification errors (Ischemic vs. others,
IM vs. others and Idiopathic vs. others) and one three-
class LOOCV misclassification error. Note that through-
out this article, three-class classification results for SC and
RF were obtained by direct applications of SC and RF,
rather than by combining multiple binary classifications.
Based on Table 1, we first note that the performances of
any classifier is sensitive to the number of top ranked
genes one starts with. For example, in the three-class clas-
sification, LASSO made 8 errors when only the top 200
genes are considered but made 18 errors when all 22283
genes are used. But there is no obvious relationship
between the gene subset size and the five methods'
performances.
In the two-class classification problem of ischemic vs. oth-
ers, PPLS, PLS, SC, LASSO and RF yielded LOOCV errors
range from 7 to 15, 6 to 13, 8 to 13, 9 to 15 and 10 to 12
respectively. The five methods obtained similar numbers
of errors in all instances. In the two-class classification
problems of IM vs. others and idiopathic vs. others, all
five methods yielded similar numbers of errors. In the
overall three-class classification, again all the five classifi-
cation methods perform similarly. There is no clear evi-
dence that one method is clearly superior to others.
In order to assess whether a gene expression profile is
affected by gender, we classified the 23 samples from male
patients only. Among the 23 samples for male patients, 9
of them are ischemic, 7 are IM and 7 are idiopathic.
Table 2 reports the LOOCV misclassification errors of
these five methods for the Minnesota data with males
only. Again, the models start from different numbers of
top ranked genes. The three two-class LOOCV misclassifi-
cation errors and one three-class LOOCV misclassification
error are estimated for each method as described before.
Based on Table 2, again we note that the classification per-
formances of PPLS, PLS, SC, LASSO and RF can be quite
sensitive to the number of top ranked genes one uses. For
example, in the one-against-others two-class classification
problem of ischemic vs. others, PPLS made 10 errors
when the top 400 genes are considered but the number of
errors suddenly increases to 14 when the top 800 genes
are used. Again there is no obvious relationship between
the gene subset size and the five methods' performances.
Comparing PPLS, PLS, SC, LASSO and RF, we find that the
five methods perform very similarly in almost all
instances. There is no evidence that any method is clearly
the best. One thing we noticed about LASSO is that when
the model contains many genes, say top 12800, then it
gives more errors than PPLS, PLS, SC and RF in the three-
class classification. This could happen by chance since we
did not observe the same trend in the decomposed one-
against-others binary classifications.
As in Table 1, the results in Table 2 suggest that discrimi-
nating ischemic group from the other two groups was less
Table 1: LOOCV errors for three-class classification with Minnesota data: all patients.
# of top 
genes
Isch vs other IM vs other Idio vs other Overall
PPLS PLS SC LSO RF PPLS PLS SC LSO RF PPLS PLS SC LSO RF PPLS PLS SC LSO RF
5 0 79 8 1 1 1 2 68 6 7 9 86 5 8 6 1 4 1 1 1 1 1 2 1 4
100 9 6 8 9 11 6 7 6 7 8 10 9 5 11 8 11 9 11 13 13
200 9 7 12 9 11 7 9 7 7 9 6 7 5 6 7 12 11 12 8 14
400 11 11 13 10 12 8 9 8 7 8 10 8 8 8 8 16 15 14 11 15
800 8 11 12 13 12 9 9 8 8 8 8 8 7 10 8 15 17 15 14 16
1600 12 12 11 11 11 9 8 8 5 8 12 8 5 7 7 16 17 13 11 13
3200 10 12 9 15 10 9 9 7 6 7 9 7 5 10 8 14 14 14 14 13
6400 11 11 10 15 10 9 10 9 8 7 9 8 5 8 8 15 14 13 15 12
9600 10 11 10 15 10 10 8 7 9 7 7 8 4 9 10 14 12 15 16 15
12800 13 12 11 15 11 7 7 7 9 7 8 8 5 10 9 15 13 15 17 17
1 6 0 0 01 31 2 1 3 1 5 1 08 7 1 097 8 851 091 51 3 1 4 1 7 1 6
1 9 2 0 01 31 2 1 3 1 5 1 19 7 1 097 8 851 081 51 4 1 4 1 7 1 7
22283 13 13 11 15 10 7 6 11 9 7 7 7 5 10 10 14 14 14 18 16BMC Bioinformatics 2005, 6:205 http://www.biomedcentral.com/1471-2105/6/205
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accurate than distinguishing IM from the other two
groups and separating idiopathic group from the other
two groups.
If we compare Table 1 (30 patients) with Table 2 (23 male
patients), we can see that the misclassification error rates
of all the five methods in Table 2 are much higher than
those in Table 1. Reduced sample size is likely a factor.
To see whether the high prediction errors are due to the
presence of the three classes, we considered a binary clas-
sification problem. We applied all the five methods to the
10 ischemic and 13 idiopathic samples. We also assessed
the classification accuracy on the male patients with 9
ischemic and 7 idiopathic samples. The classification
results were shown in Table 3.
From Table 3, we can see that all the five methods have
very similar performances in classifying ischemic and idi-
opathic samples. If we compare the classification perform-
ances of these five methods with/without female patients,
taking the sample size into consideration, we can see that
the misclassification error rates with only male patients is
much higher than those with all patients. This again is
probably because the sample size (16) with only males is
smaller. In particular, we noticed that LASSO is more sen-
sitive to the small sample size.
Table 2: LOOCV errors for three-class classification with Minnesota data: males only.
# of top 
genes
Isch vs other IM vs other Idio vs other Overall
PPLS PLS SC LSO RF PPLS PLS SC LSO RF PPLS PLS SC LSO RF PPLS PLS SC LSO RF
5 0 1 1 9 1 1 1 0 1 27 6577 5 66651 51 2 1 1 1 4 1 5
1 0 0 1 01 0 1 0 1 1 1 15 7587 5 66581 01 2 1 1 1 3 1 4
2 0 0 1 21 2 1 6 1 0 1 26 7685 6 67781 31 2 1 1 1 3 1 5
4 0 0 1 01 2 1 5 1 0 1 26 8777 5 78691 41 4 1 1 1 4 1 3
800 14 12 13 9 12 6 7 6 8 7 5 6 8 6 9 12 11 12 14 15
1600 15 15 12 7 10 6 4 7 8 6 5 5 8 8 8 13 12 13 13 17
3 2 0 0 1 11 1 1 1 1 0 1 17 7788 5 55881 41 1 1 4 1 5 1 5
6400 11 12 13 10 11 6 8 6 11 7 7 6 4 8 8 11 14 15 19 14
9600 9 11 14 9 10 7 7 6 8 7 8 7 4 8 8 13 13 13 19 15
12800 9 10 15 10 10 5 8 5 8 8 8 8 5 8 7 12 14 15 20 15
16000 13 12 15 10 9 8 6 5 8 7 9 7 5 8 7 14 12 14 20 17
19200 13 10 11 10 9 6 6 5 8 7 7 6 6 8 8 14 12 13 20 17
22283 12 11 9 10 11 7 5 5 8 8 5 5 6 8 8 15 11 14 20 15
Table 3: LOOCV errors for two-class classification with Minnesota data: ischemic vs idio-pathic.
# of top 
genes
All (23 samples) Males (16 samples)
PPLS PLS SC LASSO RF PPLS PLS SC LASSO RF
5 0 1 0 6566 1 0 9 1 1 8 1 1
1 0 0 77576 1 0 9 1 1 1 1 1 2
2 0 0 997 1 1 699 1 1 1 1 9
4 0 0 687 1 1 8998 1 2 9
8 0 0 69847 1 0 1 0 9 1 2 1 0
1 6 0 0 58888 1 0 1 0 9 1 2 1 0
3 2 0 0 91 09 81 08 81 0 1 29
6 4 0 0 7798966 1 0 1 2 9
9 6 0 0 9887866 1 0 1 2 8
1 2 8 0 0 8888 1 1 66 1 0 1 2 1 0
1 6 0 0 0 8778976 1 0 1 2 1 1
19200 11 8 6 7 11 8 7 9 12 9
2 2 2 8 3 9 1 0 579889 1 2 7BMC Bioinformatics 2005, 6:205 http://www.biomedcentral.com/1471-2105/6/205
Page 5 of 15
(page number not for citation purposes)
Other models
In the previous classification problems, we only included
linear terms of gene expression levels in a model. We also
considered expanded models including squared terms of
each gene's expression levels. The motivation is to possi-
bly improve model fitting, for instance, to avoid masking
in linear models [26]. In this way, the number of variables
in the new data is doubled (the original variables plus
their squared terms) and we have 44566 variables. We
repeated all the previous classification procedures and
found that the classification performance did not improve
(results not shown).
Classification with Minnesota data: pair-wise approach
We repeated the three-class classification with PPLS via
the pair-wise approach. The results are included in Table 4.
We assessed the classification of PPLS by including all 30
patients and with 23 male only. By comparing Table 4 to
Table 1 – 2, we can see that the PPLS via one-against-others
approach gives much smaller errors. This suggests that for
this specific problem, the one-against-others approach is
probably better. Again, we see the classification with male
patients gives much larger LOOCV misclassification error
rates.
Classification with PGA data: one-against-others 
approach
Table 5 reports the LOOCV misclassification errors of the
five methods for the PGA data. Four kinds of errors are
reported for each method: three one-against-others  two-
class LOOCV misclassification errors (Normal vs. others,
Ischemic vs. others, and Idiopathic vs. others) and one
three-class LOOCV misclassification error.
Based on Table 5, we can see that the classification per-
formances of PPLS, PLS, SC, LASSO and RF are quite sta-
ble with different numbers of top ranked genes one uses.
In the two-class classification problem of normal vs. oth-
ers, the five classification methods almost perform per-
fectly, where PPLS, PLS and RF have 0 errors in all
circumstances, SC has 0 errors in all situations except for
3 cases and LASSO has 1 error in one case and 0 errors in
all other cases. In the two-class classification problems of
ischemic vs. others and idiopathic vs. others, PPLS, PLS,
SC, LASSO and RF yielded 1–5 errors (mostly with 1–3
errors). That the problem of distinguishing normal from
the others is the easiest confirms that the normal class is
more separable from the other two classes. As for the
three-class classification, the errors range from 1 to 2 and
it is almost perfect.
Table 4: LOOCV errors for three-class classification: PPLS with 
pair-wise approach.
#of top genes Minnesota data
All patients Male
50 18 16
100 13 18
200 16 18
400 17 17
800 18 14
1600 17 16
3200 16 14
6400 15 15
9600 17 15
12800 17 14
16000 19 14
19200 14 16
22283 19 16
Table 5: LOOCV errors for three-class classification with PGA data: all patients.
# of top 
genes
Normal vs other Isch vs other Idio vs other Overall
PPLS PLS sc LSO RF PPLS PLS SC LSO RF PPLS PLS SC LSO RF PPLS PLS SC LSO RF
5 0 00 0 0 0 31 2 2 1 51 5 1 2 21 1 1 1
1 0 0 00 0 0 0 42 3 1 2 31 3 1 1 11 1 1 1
2 0 0 00 0 1 0 51 2 1 2 22 2 2 1 11 1 2 1
4 0 0 00 0 0 0 31 2 4 2 21 2 2 2 21 1 2 1
8 0 0 00 0 0 0 31 2 1 2 21 2 2 2 21 1 1 1
1600 0 0 1 0 0 2 1 2 1 2 2 2 2 2 2 2 1 1 2 1
3200 0 0 2 0 0 3 2 2 2 2 2 3 3 2 2 2 2 1 2 1
6400 0 0 2 0 0 3 2 2 1 2 2 2 3 2 2 2 2 2 2 1
9600 0 0 0 0 0 2 1 2 1 2 3 2 2 2 2 2 1 1 2 1
1 2 8 0 0 0 0 0003 12123 22221 1121
1 6 0 0 0 0 0 0002 12123 22221 1121
1 9 2 0 0 0 0 0002 12122 12221 1121
2 2 2 7 7 0 0 0002 12122 12221 1121BMC Bioinformatics 2005, 6:205 http://www.biomedcentral.com/1471-2105/6/205
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It may be argued that a classification involving normal
samples should be much easier because the normal class
is very different from the other two classes. Correct diag-
nosis between ischemic and idiopathic would be much
more challenging. Hence we conducted a two-class classi-
fication with 11 ischemic and 14 idiopathic samples. The
Table 6: LOOCV errors for two-class classification with PGA data: ischemic vs idiopathic.
# of top genes PPLS PLS SC LASSO RF
5 0 32222
1 0 0 11211
2 0 0 11212
4 0 0 11121
8 0 0 11131
1 6 0 0 11121
3 2 0 0 12111
6 4 0 0 13111
9 6 0 0 13111
1 2 8 0 0 13111
1 6 0 0 0 12111
1 9 2 0 0 11111
2 2 2 7 7 11111
Table 7: Genes selected by ≥ 4 methods in two-class classification (ischemic vs idiopathic) with Minnesota data. The last row gives the 
total numbers of the genes in the final models.
Probe Set Gene Rank PPLS PLS SC LSO RF
215066_at PTPRF: protein tyrosine phosphatase, receptor type, F 1 X X X X
212008_at UBXD2: UBX domain containing 2 X X X X
217234_s_at VIL2: villin 2 (ezrin) 3 X X X X
202092_s_at BART1: binder of Arl Two 5 X X X X
218318_s_at NLK: nemo-like kinase 7 X X X X
212062_at ATP9A: ATPase, Class II, type 9A 9 X X X X
218208_at FLJ22378: hypothetical protein FLJ22378 13 X X X X
212093_s_at MTSG1: mitochondrial tumor suppressor gene 1 14 X X X X
214543_x_at QKI: quaking homolog, KH domain RNA binding (mouse) 24 X X X X
209487_at RBPMS: RNA binding protein with multiple splicing 26 X X X X X
202877_s_at C1QR1: complement component 1, q subcomponent, receptor 1 31 X X X X
64438_at FLJ22222: hypothetical protein FLJ22222 40 X X X X
221928_at LOC283445: hypothetical protein LOC283445 44 X X X X
212556_at SCRIB: scribble 48 X X X X
202641_at ARL3: ADP-ribosylation factor-like 3 50 X X X X
201559_s_at CLIC4: chloride intracellular channel 4 64 X X X X
216231_s_at Homo sapiens transcribed sequence with strong similarity to protein pdb:3HLA 
(H.sapiens) B Chain B, Human Class I Histocompatibility Antigen A2.1 (HLA-A2.1 
Human Leucocyte Antigen)
73 X X X X X
220477_s_at C20orf30: chromosome 20 open reading frame 30 76 X X X X
208879_x_at C20orfl4: chromosome 20 open reading frame 14 88 X X X X
207630_s_at CREM: cAMP responsive element modulator 107 X X X X
212117_at ARHQ: ras homolog gene family, member Q 116 X X X X
212904_at KIAA1185: KIAA1185 protein 121 X X X X
M33197_5_at GAPD: glyceraldehyde-3-phosphate dehydrogenase 161 X X X X
213507_s_at KPNB1: karyopherin (importin) beta 1 163 X X X X
207627_s_at TFCP2: transcription factor CP2 208 X X X X
Total - - 275 22283 36 22 883BMC Bioinformatics 2005, 6:205 http://www.biomedcentral.com/1471-2105/6/205
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results are shown in Table 6. The five methods perform
almost perfectly: the misclassification errors range from 1
to 3 for all five methods in all models.
Genes identified
We consider genes remaining in a final model for each
method. To save space, we restrict attention to models
starting with all the genes for binary discrimination
between ischemic and idiopathic samples. Briefly,
LOOCV was first used to select any tuning parameters in a
method (e.g. number of components in a PLS model),
then a model with the selected parameters was fitted using
all the samples. Except that all the genes are used in a final
PLS model, for any of the other methods there may be
fewer genes remaining in the final model. In particular,
LASSO can select at most n genes with n the number of the
samples. It turned out that random forest also used many
of the genes.
Tables 7 and 8 lists the genes selected by at least four or
three methods for the Minnesota data and PGA data
respectively. It can be seen that there is no overlap at all
between the two gene lists. Although the same genes are
not identified from the two datasets, it is clear that the
beta-adrenergic signalling pathway is likely a discrimina-
tory pathway, given the inclusion of CREM in the Minne-
sota data and AKAP6 in the PGA data. Furthermore, the
inclusion of metabolic-related genes, such as ATPase and
GAPD, is not surprising given the class of ischemic tissue.
We also give the univariate ranks of the genes (based on
the F-statistics for the two classes) in the above two tables.
It shows that the two sets of genes (or more generally, the
genes in a final model) may not include some genes
ranked high in the univariate ranking while including
some ranked low, highlighting a possible limitation of
Table 8: Genes selected by ≥ 3 methods in two-class classification (ischemic vs idiopathic) with PGA data, The last row gives the total 
numbers of the genes in the final models.
Probe Set Gene Rank PPLS PLS SC LSO RF
206375_s_at HSPB3: heat shock 27kDa protein 3 1 X X X X
202430_s_at PLSCR1: phospholipid scramblase 1 2 X X X X
209948_at KCNMB1: potassium large conductance calcium-activated channel, subfamily M, 
beta member 1
3X X X
AFFX-TrpnX-5_at 4X X X X
212929_s_at KIAA0592: KIAA0592 protein 6 X X X X
221415_s_at MYCBP: c-myc binding protein 7 X X X
219099_at C12orf5: chromosome 12 open reading frame 5 8 X X X
219383_at FLJ14213: hypothetical protein FLJ14213 10 X X X X
208846_s_at VDAC3: voltage-dependent anion channel 3 11 X X X X
205359_at AKAP6: A kinase (PRKA) anchor protein 6 12 X X X
202324_s_at GOCAP1: golgi complex associated protein 1, 60 kDa 14 X X X X
208736_at ARPC3: actin related protein 2/3 complex, subunit 3, 21 kDa 15 X X X
215700_x_at CPNE6: copine VI (neuronal) 16 X X X
207600_at KCNC3: potassium voltage-gated channel, Shaw-related subfamily, member 3 17 X X X
217386_at 18 X X X
200961_at SPS2: selenophosphate synthetase 2 19 X X X X
211476_at MYOZ2: myozenin 2 21 X X X
209682_at CBLB: Cas-Br-M (murine) ecotropic retroviral transforming sequence b 22 X X X
208769_at EIF4EBP2: eukaryotic translation initiation factor 4E binding protein 2 23 X X X
208162_s_at FLJ10232: hypothetical protein FLJ10232 25 X X X
210500_at NICE-4: NICE-4 protein 26 X X X
216721_at LOC253512: hypothetical protein LOC253512 27 X X X
206475_x_at CSH1: chorionic somatomammotropin hormone 1 (placental lactogen) 28 X X X
210561_s_at WSB1: SOCS box-containing WD protein SWiP-1 29 X X X
206598_at INS: insulin 30 X X X
219293_s_at PTD004: hypothetical protein PTD004 75 X X X
207431_s_at DEGS: degenerative spermatocyte homolog, lipid desaturase (Drosophila) 139 X X X
205207_at IL6: interleukin 6 (interferon, beta 2) 272 X X X
221775_x_at RPL22: ribosomal protein L22 1043 X X X
200897_s_at KIAA0992: palladin 1175 X X X
total - - 32 22277 7 22 548BMC Bioinformatics 2005, 6:205 http://www.biomedcentral.com/1471-2105/6/205
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solely depending on univariate ranks to select important
genes.
More numerical results
PLS plots
To further explore why the methods all work much better
for the PGA data than for the Minnesota data, we drew
some plots using the first and the second PLS components
for binary classification of ischemic vs idiopathic groups.
We found that, for both datasets, there was a clear separa-
tion between the two groups. However, in LOOCV,
although again the two groups were separable for both
datasets, the left-out sample was more likely to be closer
to the other group than to its true group for the MInnesota
data, leading to a high LOOCV error rate; Figure 1 gives
two examples. In contrast, in the PGA data, a left-out sam-
ple tended to be close to its true group, resulting in a low
LOOCV error rate. For more details see Supplemental
Materials.
Permutation tests
Because of high misclassification error rates with the Min-
nesota data, it is of interest to investigate whether there is
any signal at all in the data. This can be accomplished by
a permutation test that compares misclassification errors
resulting from using the original data with that from ran-
domly permuted data; a P-value is defined as the propor-
tion of permuted datasets with misclassification errors
fewer than that of the original data. To generate a ran-
domly permuted data, we randomly permute the class
labels of the original data. Because all the methods have
similar performance, we consider the nearest shrunken
centroid method with the Minnesota data. Tables 9 and
10 summarize the results of misclassification errors for 50
randomly permuted datasets for three- and two-class clas-
sifications respectively. It can be seen that the
misclassification errors based on the original data are
fewer than that based on the permuted data, leading to
small P-values. This implies that, although there are rela-
tively high misclassification error rates with the Minne-
sota data, the methods perform significantly better than a
random guess.
Simulations
We did a simulation study to further evaluate the perform-
ance of the five classification methods. To mimic the real
data, simulated data were generated from either a fitted
PPLS or a fitted LASSO model to the Minnesota data com-
paring ischemic vs idiopathic, each containing top 50
genes in the initial model. Specifically, suppose that   is
the fitted response value for sample i based on the original
Minnesota data using PPLS or LASSO. Note that   is a
real number without being dichotomized yet. Suppose
that Yi = 1 or -1 is the class label of sample i in the original
data, and  . To generate a simu-
lated data, we independently draw   from Normal dis-
tributions   for  i = 1, ..., 23 and b = 1, ..., 50. Then
we apply each method to a simulated dataset
, where Xi is the gene expres-
sion profile of sample i in the original Minnesota data,
and obtain fitted values  ; the resulting misclassifica-
tion error number for dataset b  is
.
Table 11 summarizes the distributions of the misclassifi-
cation errors of each method based on 50 simulated data
with either PPLS or LASSO as the true model. It can be
seen that in general all the methods perform similarly,
though random forest seems to be most stable and has a
slight edge, and the performance of LASSO and nearest
shrunken centroid may deteriorate as the number of the
genes included in a model is increased. We also did other
PLS plots for two cases in LOOCV for the Minnesota data  comparing ischemic vs idiopathic Figure 1
PLS plots for two cases in LOOCV for the Minnesota data 
comparing ischemic vs idiopathic. In both cases, the new 
sample labeled as "N" (i.e. left-out sample in LOOCV), 
belonging to class 1 and 2 respectively in the top and the bot-
tom panels, is closer to the other group different from its 
true class, leading to misclassifications.
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simulations with the true models starting from various
numbers of top genes and various noise levels, and
observed similar phenomena: for details see Supplemen-
tal Materials.
Discussion
With more and more statistical methods being proposed
for discriminant analysis for gene expression data, it has
become increasing important to compare and evaluate
their performances with real data, as it has been done in
other contexts [27]. Comparing the five new methods
with each other using the two real datasets, we did not
find anyone uniformly better than the others. This may be
disappointing to someone who wishes to find the best sta-
tistical method. However, in the current application, the
similar performance of all the five methods on each of the
two datasets provides reassurance on the interesting
observation that it is not equally easy to distinguish the
different etiologies of heart failure using expression pro-
files in the two datasets.
Both the one-against-others  approach and the pair-wise
approach have been widely used in extending a binary
classifier to multi-class settings. Our result suggests that, at
least for the two datasets used here, the one-against-others
approach is better, which was found to be true with sup-
port vector machines but in general should also depend
on which binary classifier is used [28]. We also have
observed that any of the five methods may be sensitive to
the number of genes being included. This is particularly
relevant because, although all the five methods (and
many other methods) can handle any large number of
genes, this does not dismiss the potential importance of a
user's preliminary ranking and screening of genes. Of
course, all our observations here are based on the two
datasets without consideration of statistical variability,
further studies are needed to validate these points.
An interesting finding of this work is that it is difficult to
discriminate the different etiologies of human heart fail-
ure using one gene expression dataset, and at the same
time, it is quite easy for the other dataset. A possible expla-
nation is the different types of the microarray chips used:
Affymetrix HG-U133A chips were used in the Minnesota
study while Affymetrix HG-U133 plus 2 chips were used
in the PGA study. Because the HG-U133 plus 2 chips con-
tain more genes (or ESTs), to minimize the effects of using
different genes, we only used the genes present in the Min-
nesota data and still yielded much better performance for
the PGA data. In fact, we used all the genes in the PGA
data and obtained similar results for the PGA data.
Although we can say that the performance difference in
the two datasets is not caused by different genes contained
on a chip, we do not know whether the more recent HG-
U133 plus 2 chips provide more reliable measurements
on gene expression. In addition, quality control criteria
Table 9: LOOCV three-class misclassification errors with the original Minnesota data and the percentiles of LOOCV errors with 50 
permuted datasets by SC.
# of top genes Original data Permutated data
LOOCV errors P-value 0% 25% 50% 75% 100%
50 11 .00 13 17 20 22.75 29
100 11 .00 12 17.25 20 22 30
400 14 .02 13 18 20.5 23 28
1 6 0 0 1 3. 0 01 31 82 02 32 9
6 4 0 0 1 3. 0 21 21 82 02 32 9
Table 10: LOOCV two-class misclassification errors with the original Minnesota data and the percentiles of LOOCV errors with 50 
permuted datasets by SC: ischemic vs idiopathic.
# of top genes Original data Permutated data
LOOCV errors P-value 0% 25% 50% 75% 100%
50 5 .00 5 10 11 12.75 19
100 5 .00 5 10 11 12 19
4 0 07. 0 64 9 1 11 31 7
1600 8 .08 5 9.25 11.5 13 17
6 4 0 0 9. 1 26 1 01 11 32 1BMC Bioinformatics 2005, 6:205 http://www.biomedcentral.com/1471-2105/6/205
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for the inclusion of a chip were nearly identical between
the two datasets. We would suspect that the performance
difference may be the result of different patient popula-
tions and different study protocols (e.g. lack of clearly pre-
specified patient inclusion/exclusion criteria). As dis-
cussed in [29], a key to validating any prognostic and
diagnostic biomarkers is the use of data that can reflect the
full range of clinical variability. This highlights the impor-
tance of utilizing multiple datasets drawn from multiple
subpopulations. Even for the purpose of prediction for
one subpopulation, it is possible to improve the perform-
ance by borrowing information from other subpopula-
tions [30]. It can be argued that the performance should
be weighted on the complexity of the disease. Challenges
with the current clinical discrimination of ischemic versus
non-ischemic heart failure is indeed why defining poten-
tial gene expression biomarkers may be a helpful addi-
tional approach in this characterization. A recognized
limitation of utilizing heart tissue to identify biomarkers
is the difficulty of collecting tissue. In summary, the cur-
rent and other studies stress the importance of collaborat-
ing efforts to share tissue/data to strengthen the search for
applicable biomarkers.
Conclusions
Many studies have aimed to develop new statistical and
machine learning methods for best sample discrimina-
tion. Our results suggest that, at least for some gene
expression data, several existing methods may work
almost equally well. More importantly, because of the
quite different performances of the methods on the two
datasets, one must remain cautious when assessing the
performance of sample discrimination using a small gene
Table 11: Percentiles of misclassification errors from 50 simulated datasets for two-class classification. The true model is either PPLS 
or LASSO fitted with top 400 genes to the Minnesota data to compare ischemic vs idiopathic.
Methods # of top genes True model: PPLS True model: LASSO
Mean 0% 25% 50% 75% 100% Mean 0% 25% 50% 75% 100%
P P L S 5 0 2 . 5 4 0 223 6 00 000 0
100 2.6 1 1.25 2 3 7 1 1 1 1 1 1
4 0 0 2 . 5 8 0 223 7 00 000 0
1600 2.62 0 2 2 3.75 7 0 0 0 0 0 0
6400 2.6 0 2 2 3 6 0 0 0 0 0 0
P L S 5 0 2 . 5 8 0 223 6 00 000 0
1 0 0 2 . 6 0 223 7 00 000 0
4 0 0 2 . 5 6 0 223 7 00 000 0
1600 2.52 0 2 2 3 7 0 0 0 0 0 0
6400 2.54 0 2 2 3 6 0 0 0 0 0 0
LASSO 50 2.48 0 2 2 3 6 0 0 0 0 0 0
1 0 0 2 . 4 8 0 223 6 00 000 0
4 0 0 2 . 8 4 0 2231 0 00 000 0
1600 3.48 0 2 2 4.75 10 0 0 0 0 0 0
6400 3.48 0 2 2 4.75 10 0 0 0 0 0 0
SC 50 2.76 1 2 2 3 7 1 1 1 1 1 1
1 0 0 2 . 7 4 1 223 7 11 111 1
400 2.96 0 2 3 3.75 7 0.28 0 0 0 1 1
1600 3.58 0 2 3 5 8 0 0 0 0 0 0
6400 4.08 1 3 4 5 10 1 1 1 1 1 1
RF 50 2.48 0 2 2 3 6 0 0 0 0 0 0
1 0 0 2 . 4 8 0 223 6 00 000 0
4 0 0 2 . 4 8 0 223 6 00 000 0
1600 2.48 0 2 2 3 6 0 0 0 0 0 0
6400 2.48 0 2 2 3 6 0 0 0 0 0 0BMC Bioinformatics 2005, 6:205 http://www.biomedcentral.com/1471-2105/6/205
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expression dataset; it may be necessary to use larger or
multiple datasets to draw a more reliable conclusion.
Methods
Binary classifiers: PLS, PPLS and LASSO
We first briefly review the three binary classifiers, which
was first designed for regression and can be directly
applied to two-class classification, even when the number
of covariates (i.e. genes here) is much larger than the sam-
ple size.
We code the response variable (i.e. class label) as Y = 1 for
class 1 and Y = -1 for class 2. Suppose that xi is the expres-
sion level of gene i, i = 1, ..., p with p as the total number
of the genes, and that we have n samples in the training
data. A challenge is that we have n <<p.
The main idea of partial least squares (PLS) [21] is to seek
a few linear combinations of 
for j = 1, ..., m, then apply ordinary least squares (OLS) to
regress Y on zj's to obtain
with β's as OLS estimates. The key of course is how to form
linear components zj's. It turns out that
αj = argmaxαCorr2(y, Xα) Var(Xα)
with the constraints ||α|| = 1,   for l = 1,..., j - 1,
where y is the vector of observed Y's (in the training data),
X is the design matrix (i.e. matrix of observed x's), and S is
the sample covariance matrix of x's [31]. In practice, the
number of linear components m has to be chosen, typi-
cally by a form of cross-validation, such as leave-one-out
cross-validation (LOOCV), to minimize misclassification
errors.
PPLS is a penalized regression method in the framework
of PLS [19,32]. Suppose that we have built a PLS linear
model, which can be rewritten as:
Then we shrink the PLS coefficients by soft-thresholding
[33,34]
where sign(a) = 1 if a ≤ 0 and sign(-a) = -1 if a < 0, λ is a
shrinkage parameter to be determined, and f+ = max(f, 0).
It is common that the shrinkage leads to many  ,
effectively eliminating gene i from the model, thus gene
selection is automatically accomplished. Next we con-
struct a linear component  . Finally a PPLS
model is built by regressing Y on z using OLS
which can be re-expressed as  . The
parameters involved in building a PPLS model, such as
the shrinkage parameter λ and the number of PLS compo-
nents, are estimated by LOOCV. The goal is to choose the
largest shrinkage parameter and the smallest number of
PLS components for which the LOOCV misclassification
error estimate is minimized.
The LASSO estimates [23] in a linear model
are obtained by
subject to  , where Yi is the observed response
for sample i and   is its LASSO estimate, i = 1, ..., n,
and t can be chosen by LOOCV. The constraint can often
force many  , leading to gene selection.
Note that the class label (1/-1) for the response Y  is
binary, but in any of the above binary classifiers, the
response Y is treated as a continuous variable and the esti-
mate   could be any real number. To predict the class of
a new sample, we use sign( ): if the estimated response
 is greater than or equal to 0, then we classify it into
class 1; otherwise, class 2. In particular, this direct use of
PLS for binary classification (as in [35]) is different from
other approaches [36-40]; a distinct advantage of our
approach is its simplicity, e.g., avoiding convergence
problems when two classes are perfectly separable, which
is common in microarray data with a small sample size
and a large number of genes.
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Multiclass classifiers: nearest shrunken centroids and 
random forest
Nearest shrunken centroids (SC) is built on a diagonal-
ized linear discriminant analysis (DLDA) [26,41]. Sup-
pose that we have K classes,   is the mean expression
level of gene i in class k of the training samples,   is the
pooled sample variance of gene i of the training samples,
and πk is the prior probability of a new sample being in
class k. The DLDA rule for a new sample 
is
SC is motivated from the observation that many of the
genes will not be predictive of the class membership and
should be eliminated from the above DLDA rule. For-
mally, define
where nk is the number of training samples in class k, and
 is the overall mean expression level of gene i in all the
training samples. Note that by the definition, we have
. Let
for all i and k, where ∆ is the shrinkage parameter to be
chosen by LOOCV. Then substituting   in the DLDA
rule by  , we obtain a SC rule
The new sample x* is assigned to class k0  such that
.
Note that, if  , then   and thus gene i plays
no role in classifying for class k. Hence SC effectively
accomplishes gene selection by shrinkage.
Random forest (RF) [24] is an ensemble of classification
trees [42,43], which have been shown to be useful in
tumor classification with microarray data [44]. It is
designed to improve over a single classification tree. There
are two random aspects that help generate multiple classi-
fication trees in RF. First, a bootstrap sample is repeatedly
drawn from the original training data and then used to
build a classification tree. Second, in building a classifica-
tion tree, rather than using the best splitting variable (i.e.
gene here) from all the available variables at each node, it
chooses the best from a small random subset of all the var-
iables. Each tree is grown to the maximum and no prun-
ing is pursued. To predict the class for a new sample, the
sample is applied to each tree and each tree votes by giving
its prediction, then the majority vote is taken as the final
prediction for the sample.
Extending a binary classifier to multiclass classification
Here we describe how a multi-class (K > 2) classification
problem can be handled by a binary classifier, such as
PLS, PPLS and LASSO. It is achieved by formulating a
multi-class classification problem as multiple two-class
classification problems. We consider two most popular
approaches: one is to compare each class against all the
others, and the other is to compare all possible pairs of
classes. Applications of these two approaches can be
found, among others, in [45-50]. In particular, some have
considered the first approach for PLS [50].
The one-against-others approach is to reduce a K-class clas-
sification task to K two-class classification problems. For-
mally, a new response is defined in the kth binary problem
as:
for k = 1, ..., K. Then we build K binary classifiers. To pre-
dict a new sample with gene expression profile x*, we
apply x* to each binary classifier and yield  . Finally, the
class of the new sample C(x*) is predicted as
That is, the new sample is classified into the class maxi-
mizing .
The pair-wise approach reduces a K-class classification to
K(K - 1)/2 two-class classification problems [45]. Specifi-
cally, for each of all possible pairs of classes, solve each of
the two-class problems and then, for a new sample, com-
bine all the pairwise decisions to form a K-class decision.
Suppose that the new binary response in a pairwise com-
parison with classes k1 and k2 (with 1 ≤ k1 <k2 ≤ K) is
defined as
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We build a binary classifier with response   using
only samples belonging to class k1 or k2, and denote the
fitted response value for a new sample with expression
profile x* as  . As described earlier, we classify the
new sample into class k1 or k2 according to the sign of
. After this is done for any 1 ≤ k1 <k2 ≤ K, the final
decision is to assign the new sample to the class that wins
the most pairwise comparisons. In the case when there are
multiple winning classes, we randomly pick one of the
winning classes to be the final winning class. Comparing
to the one-against-others approach, the pair-wise approach
is computationally more expensive if K ≥ 4.
Gene ranking
To explore the effect of the number of genes a model starts
with on the classification performance, we have a prelim-
inary gene ranking using a usual F-statistic. This univariate
ranking is used throughout, and obviously is by no means
to be optimal. For the purpose of the presentation in this
section, we only need to consider a given gene. Suppose xik
is the gene expression level of the gene in sample i that is
in class k, i = 1, ..., nk, and k = 1, ..., K, where nk is the total
number of samples in class k and K is the total number of
classes. Let   be the mean expression level of class-k
samples,   be the overall mean (across all the samples)
and   be the total number of samples. We can
construct an F-statistic as the ratio of the mean sums of
squares for between-class and within-class variations:
We can rank all the genes based on their corresponding F-
statistics: a gene with a larger F-statistic indicates a
stronger relationship between its expression levels and the
class membership in the samples, and therefore has a
higher rank as a potential predictor of the class. We started
with various models by including different numbers of
top ranked genes. We considered models starting from the
top 50, 100, 200, 400, 800, 1600, 3200, 6400, 9200,
12800, 16000, 19200, and all (22283 and 22277 for the
two datasets respectively) genes respectively.
It is an incorrect practice in microarray experiments to first
select genes using all the samples and then perform cross-
validation using the selected genes, which gives down-
ward biased prediction error estimates [51,52]. Hence, it
is essential to perform cross-validation on the entire
model building process, including gene selection. In our
study, we did honest cross-validation. In particular, we
cross-validated gene selection (and other aspects of model
building, such as parameter selection and estimation).
Specifically, in LOOCV, we remove each sample from the
data in turn (which is then treated as the test sample),
carry out gene selection using F-statistic based on the
remaining samples, build a classifier with the selected
genes using the remaining samples, and then test the clas-
sifier on the left-out sample.
Data preprocessing
To facilitate the application of penalized regression (i.e.
PPLS and LASSO) so that their regression coefficients are
in the same unit and thus can be penalized using a global
penalty parameter, the expression levels of each gene were
scaled to have sample variance 1.
Evaluations
In addition to PLS/PPLS, we will consider the shrunken
centroids (SC) method, the LASSO, and the random forest
(RF). SC, LASSO and RF have been implemented in R
[53], and are easy to use; we applied their R functions
using default parameter settings. SC and RF are directly
applicable to multiclass classification while LASSO, as
PLS/PPLS, is itself a binary classifier. For multi-class clas-
sification with PLS and LASSO, we used the same
approaches as described for PPLS.
We use the leave-one-out cross-validation (LOOCV) to
estimate the prediction error for each of the methods.
Within this first-level LOOCV, a second-level LOOCV is
used to select tuning parameters for each method to min-
imize cross validation errors. Specifically, in PLS, the
smallest number of PLS components is selected among
the PLS models that give the minimum LOOCV error. In
PPLS, among the models with minimum LOOCV error,
we first pick the ones with the smallest number of PLS
components, then pick the one with the largest shrinkage
parameter. In the SC method, the largest shrinkage is
selected among the models that minimize the LOOCV
error. The number of candidate threshold values and the
number of cross validation folds are both set to be default
(i.e. 30 and the smallest class size respectively). In LASSO,
the maximum fraction parameter of the models that min-
imize LOOCV error is selected while the number of the
candidate fraction values is set to be 51 (equally spaced
from 0 to 1) and the number of cross validation folds is
set to be the total sample size. In RF, every parameter is set
to be default. For example, the number of trees to grow is
set to 500, and the number of candidate splitting variables
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considered at each split is set to   by default, where p is
the total number of variables (i.e. genes).
Due to the small sample size (about 10 in each class) in
each dataset, it is quite challenging to estimate the predic-
tion error well. Although it is straightforward to apply
LOOCV or other cross-validation methods, their perform-
ance may not be optimal. After submitting this work, we
became aware of the recent work by Fu et al [54], where a
better method than LOOCV was proposed specifically for
microarray data. This new method aims to reduce the var-
iability of LOOCV. We reason that with the use of this new
method, the main conclusions drawn in this work would
not change.
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